Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2008-11-12
2010-11-30
Aeder, Sean E (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
Reexamination Certificate
active
07842789
ABSTRACT:
Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-α (TNF-α), human tissue factor (TF), human α4β7integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor α-chain (TAC) for diagnostic and therapeutic applications.
REFERENCES:
patent: 4002531 (1977-01-01), Royer
patent: 4179337 (1979-12-01), Davis et al.
patent: 4515893 (1985-05-01), Kung et al.
patent: 4732863 (1988-03-01), Tomasi et al.
patent: 5091313 (1992-02-01), Chang
patent: 5147537 (1992-09-01), Sada et al.
patent: 5166322 (1992-11-01), Shaw et al.
patent: 5169627 (1992-12-01), Cunningham-Rundles
patent: 5527528 (1996-06-01), Allen et al.
patent: 5532150 (1996-07-01), Snow et al.
patent: 5595732 (1997-01-01), Hakini et al.
patent: 5618920 (1997-04-01), Robinson et al.
patent: 5620689 (1997-04-01), Allen et al.
patent: 5622700 (1997-04-01), Jardieu et al.
patent: 5643575 (1997-07-01), Martinez et al.
patent: 5661020 (1997-08-01), Snow et al.
patent: 5670132 (1997-09-01), Griffiths et al.
patent: 5672347 (1997-09-01), Aggarwal et al.
patent: 5677426 (1997-10-01), Fong et al.
patent: 5679532 (1997-10-01), Repine et al.
patent: 5686070 (1997-11-01), Doerschuck et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5695760 (1997-12-01), Faanes et al.
patent: 5698196 (1997-12-01), Matsushima et al.
patent: 5702946 (1997-12-01), Doerschuk et al.
patent: 5707622 (1998-01-01), Fong et al.
patent: 5714338 (1998-02-01), Wai Fei et al.
patent: 5725856 (1998-03-01), Hudziak et al.
patent: 5726037 (1998-03-01), Bodary et al.
patent: 5739277 (1998-04-01), Presta et al.
patent: 5766897 (1998-06-01), Braxton
patent: 5874080 (1999-02-01), Herbert et al.
patent: 6025158 (2000-02-01), Gonzalez et al.
patent: 6117980 (2000-09-01), Gonzalez et al.
patent: 6133426 (2000-10-01), Gonzalez et al.
patent: 6458355 (2002-10-01), Hsei et al.
patent: 6468532 (2002-10-01), Hsei et al.
patent: 6870033 (2005-03-01), Hsei et al.
patent: 7005504 (2006-02-01), Hsei et al.
patent: 7122636 (2006-10-01), Hsei et al.
patent: 7214776 (2007-05-01), Hsei et al.
patent: 7507405 (2009-03-01), Hsei et al.
patent: 0239400 (1987-09-01), None
patent: 420937 (1994-11-01), None
patent: 770628 (1997-05-01), None
patent: WO 92/04372 (1992-03-01), None
patent: WO 93/04173 (1993-09-01), None
patent: WO 94/10202 (1994-05-01), None
patent: WO 94/11026 (1994-05-01), None
patent: WO 94/12219 (1994-06-01), None
patent: WO 94/21235 (1994-09-01), None
patent: WO 95/11987 (1995-05-01), None
patent: WO 95/15769 (1995-06-01), None
patent: WO 95/23813 (1995-09-01), None
patent: WO 95/23865 (1995-09-01), None
patent: WO 95/32003 (1995-11-01), None
patent: WO 96/02576 (1996-02-01), None
patent: WO 96/09325 (1996-03-01), None
patent: WO 96/22785 (1996-08-01), None
patent: WO 96/23065 (1996-08-01), None
patent: WO 96/34015 (1996-10-01), None
patent: WO 96/40210 (1996-12-01), None
patent: WO 96/40731 (1996-12-01), None
patent: WO 97/01354 (1997-01-01), None
patent: WO 97/10847 (1997-03-01), None
patent: WO 97/26912 (1997-07-01), None
patent: WO 97/40215 (1997-10-01), None
patent: WO 98/06248 (1998-02-01), None
patent: WO 98/23761 (1998-06-01), None
patent: WO 98/25971 (1998-06-01), None
patent: WO 98/37200 (1998-08-01), None
patent: WO 98/45331 (1998-10-01), None
patent: WO 98/51793 (1998-11-01), None
patent: WO 99/01556 (1999-01-01), None
patent: WO 99/37779 (1999-07-01), None
Zapata et al (FASEB J. 9:A1476, 1995).
Rathjen et al (Br. J. Cancer, 1992, 65: 852-856).
Abuchowski and Davis, “Soluble Polymer-Enzyme Adducts”Enzymes as Drugs, Holcenberg, JS; Roberts, J. eds., New York; Wiley, Chapter 13, pp. 367-383 (1981).
Adagen LabelPhysicans Desk Reference(Product Information) 48 edition, Montvale, NJ; Medical Economics Data Production Company pp. 917-918 (1994).
Allen et al., “A new strategy for attachment of antibodies to sterically stabilized lipsomes resulting in efficient targeting to cancer cells”Biochimica et Biophysica Acta1237 (2):99-108 (Jul. 26, 1995).
Anderson and Tomasi, “Polymer modification of antibody to eliminate immune complex and Fc binding”Journal of Immunological Methods109(1): 37-42 (Apr. 22, 1988).
Beauchamp et al., “A new peocedure for the synthesis of polythylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and α2-macroglobulin—Analytical Biochemistry 131 (1)”: 25-33 (1983).
Bernard et al., “The American-European Consensus Conferences on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trail coordination”American Journal of Respiratory&Critical Care medicine149 (3 pt 1):818-824 (Mar. 1994).
Brooks and Stocks, “Use of polyacrylamide-derivatized antibody in dextran-poly (ethylene glycol) systems”Methods in Enzymology228:390-395 (1994).
Brumeanu et al., Derivatization with monomethoxypolyethylene glycol of Igs experssing viral epitopes obviates adjuvant requirements :Journal of Immunology154(7):3088-3095 (Apr. 1, 1995).
Carter et al., “Preparation and uses of Fab' fragments fromEsherichia coli” Antibody Engineering: a Practical Approach, Hoogenboom, H., McCafferty, J. Chiswell, D., eds., Oxford, UK:IRK Press, Chpt. 13 pp. 291-308 (1996).
Chamow et al., Modification of CD4 immunoadhesin with monomethoxypoly (ethylene glycol) aldehyde via reductive alkylation:BioconjugateChemistry5 (2): 133-140 (Mar.-Apr. 1994).
Chapman, et al., Therapeutic antibody fragments with prolonged in vivo hlaf-livesNature Biotechnology17 (8):780-783 (Aug. 1999).
Clark et al., “Long-acting growth hormones produced by conjugation with polyethylene glycol”Journal of Biological Chemistry271 (36):21969-21977 (Sep. 6, 1996).
Cunningham-Rundles, et al., Biological activites of polyethylene-glycol immunoglobulin conjugates. Resistance to enzymatic degradation:Journal of Immunological Methods152 (2):177-190 (Aug. 10, 1992).
Delgado et al., “Analytical partitioning of poly (ethylene glycol) modified proteins”Journal of Biological Chromotography B692 (2):263-272 (May 9, 1997).
Delgado, et al., “Distinct Influence of PEGylation on the Tumour Localisation of Transferrin and a Tumour-specific Fab Fragment (f9)”Journal of Cellular Biochemistry(Abst. A4-101, Keystone Symposium held at Hilton Head Island, SC, Jan. 7-13, 1995) Suppl. 19A:171 (1995).
Delgado, et al., “Enhanced tumour specificaity of an anti-carcinoembrionic antigen Fab' fragment by poly (ethylene glycol) (PEG) modification”British Journal of Cancer73(2): 175-182 (Jan. 1996).
Delgado, et al., “The uses and properties of PEG-linked proteins”Crtical Reviews in Therapeutic Drug Carrier Systems9 (3-4):249-304 (1992).
Duel, et al., “Amino acid Sequence of human platelet factor 4”Proc. Natl. Acad. Sci. 74:2256-2258 (1977).
Donnelly, et al., :Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groupsLancet341 (8846):643-647 (Mar. 13, 1993).
Elling and Kula, Immunoaffinity partitoning: synthesis and use of polyethylene glycol-oxirane for coupling to bovine scrum albumin and monoclonal antibodies:Biotechnology and Applied Biochemistry13 (3):354-362 (Jun. 1994).
Eno-Amooquaye et al., “Altered biodistribution of an antibody-enzyme conjugate modified with polyethylene glycol”British Journal of Cancer73(11):1323-1327 (Jun. 1996).
Folkesson, et al., “Acid aspiration-induced
Hsei Vanessa
Koumenis Iphigenia
Leong Steven
Shahrokh Zahra
Zapata Gerardo
Aeder Sean E
Dreger Ginger R.
Fox James A.
Genentech Inc.
Svoboda Craig
LandOfFree
Antibody fragment-polymer conjugates and uses of same does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibody fragment-polymer conjugates and uses of same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody fragment-polymer conjugates and uses of same will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4240624